Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson
07:05pm, Tuesday, 15'th Oct 2024
BRIDGEPORT, Conn.--(BUSINESS WIRE)--A Bridgeport jury has awarded Evan Plotkin and his wife Martha Barry-Plotkin $15 million in a verdict against pharmaceutical giant Johnson & Johnson (NYSE:JNJ) and
J&J must pay $15 mln to Connecticut man who says its talc gave him cancer, jury finds
03:45pm, Tuesday, 15'th Oct 2024
Johnson & Johnson must pay $15 million to a Connecticut man who alleges that he developed mesothelioma, a rare form of cancer, as a result of using the company's talc powder for decades, a jury found
3-Stock Lunch: UnitedHealth, Johnson & Johnson & Wolfspeed
03:30pm, Tuesday, 15'th Oct 2024
Jay Hatfield, Infra-Cap CEO, joins 'Power Lunch' to discuss stock plays for three stocks.
Are JNJ's mergers and acquisitions weighing down company's performance?
02:20pm, Tuesday, 15'th Oct 2024
Johnson & Johnson (JNJ) stock is experiencing a positive trading day following the announcement of its Q3 results for 2024. The earnings per share (EPS) surpassed estimates, although improved business
Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results
02:14pm, Tuesday, 15'th Oct 2024
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 150 points on Tuesday.
J&J beats Q3 earnings estimates, raises full-year sales guidance
12:51pm, Tuesday, 15'th Oct 2024
Johnson & Johnson (NYSE:JNJ) shares moved higher after the pharmaceutical giant posted better-than-expected results for the third quarter. Earnings per share (EPS) of $2.42 were down from $2.66 in the
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
12:31pm, Tuesday, 15'th Oct 2024
Johnson & Johnson (NYSE:JNJ ) Q3 2024 Earnings Conference Call October 15, 2024 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman & Chief Exec
J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS Guidance
12:30pm, Tuesday, 15'th Oct 2024
JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.
J&J CFO Wolk on Product Pipeline, Strategy and Talc Lawsuit
11:54am, Tuesday, 15'th Oct 2024
Johnson & Johnson CFO Joseph Wolk discusses the company's product pipeline, acquisition strategy and the latest on the talc baby powder lawsuit on "Bloomberg Open Interest." J&J reported stronger-tha
How to play biotech stocks: Johnson & Johnson, Pfizer
10:47am, Tuesday, 15'th Oct 2024
Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins Market Domination Hosts Julie Hyman and Josh Lipton to break down how to play biotech and pharmaceutical
Blue Chip Faces Off With Resistance After Earnings
10:44am, Tuesday, 15'th Oct 2024
Shares of Johnson & Johnson (NYSE:JNJ) are up 2.4% to trade at $165.43 this morning, after the company posted a third-quarter beat and hiked its full-year revenue guidance.
Johnson & Johnson Posts Weaker-Than-Expected Profit on Billions in Legal Costs
10:35am, Tuesday, 15'th Oct 2024
Johnson & Johnson (JNJ) posted better sales than expected for the third quarter, but profit fell short of analysts' estimates as the company reported billions in one-time expenses like legal costs and
Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to Say
10:31am, Tuesday, 15'th Oct 2024
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metr
Johnson & Johnson Q3: Strengthening Cardiovascular Device Portfolio
10:01am, Tuesday, 15'th Oct 2024
I reiterate a “Buy” rating for Johnson & Johnson, driven by their robust cardiovascular device portfolio and recent acquisitions, with a fair value of $195 per share. The acquisition of V-Wave enh
J&J CFO Joseph Wolk on Q3 results: Earnings beat driven by pharmaceuticals
08:37am, Tuesday, 15'th Oct 2024
Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, R&D investment, growth outlook, state of the company's talc settl
